Onyx's Shares Plummeted on NSCLC Data

February 2008
Bioworld Week;2/25/2008, Vol. 16 Issue 8, p2
The article reports on the 26.4% drop of shares of Emeryville, California-based Onyx Pharmaceuticals Inc. due to the termination of the Phase III study of Nexavar, a non-small-cell lung cancer drug. It notes that the termination of the trial is associated with the lack of efficacy of the Nexavar. It also mentions the high mortality observed in patients who received Nexavar.


Related Articles

  • Bayer and Onyx halt Phase III lung cancer trial.  // PharmaWatch: Biotechnology;Apr2008, Vol. 7 Issue 4, p6 

    The article reports that Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals Inc. have ceased the clinical trial for Nexavar tablets, a drug for treating patients with non-small cell lung cancer (NSCLC). It was stated that the pharmaceutical companies stopped the drug's Phase III...

  • Nexavar Boosts Liver Cancer Survival By 44%.  // Bioworld Week;6/11/2007, Vol. 15 Issue 24, p3 

    The article discusses the results of a phase III trial of Nexavar by Onyx Pharmaceuticals Inc. and Bayer Healthcare Pharmaceuticals Inc. announced at the 2007 American Society of Clinical Oncology in Chicago, Illinois. Data showed an increase in overall survival in liver cancer patients...

  • COMPANY SPOTLIGHT - Bayer AG.  // PharmaWatch: Cancer;Jun2006, Vol. 5 Issue 6, p20 

    The article reports on the orphan drug status granted in the U.S. and Europe for Bayer and Onyx Pharmaceuticals' Nexavar, for the treatment of liver cancer. Stability in disease as well as tumor shrinkage were experienced by patients treated with Nexavar. Ongoing is a randomized phase II trial...

  • Onyx Soars as Nexavar Hits Goal in Phase II.  // Bioworld Week;7/27/2009, Vol. 17 Issue 30, p4 

    The article reports that Onyx Pharmaceuticals Inc.'s share has increased after its multikinase inhibitor Nexavar met the primary endpoint in a Phase II trial. It notes that the result drove the company's stock up 6.03 dollars, closing July 22, 2009 at 34.72 dollars. The data reveals that the...

  • Clinic Roundup.  // BioWorld Today;2/24/2012, Vol. 23 Issue 37, p10 

    This section offers news briefs on clinical trials including the enrollment completed by Onyx Pharmaceuticals Inc. in a trial of carfilzomib for relapsed multiple myeloma, number of trial sites opened by Northwest Biotherapeutics in the U.S. for a study of DCVax-L immune therapy in glioblastoma...

  • Cancer News Round-up.  // PharmaWatch: Monthly Review;Sep2006, Vol. 5 Issue 9, p4 

    The article reports developments in the pharmaceutical industry worldwide from July 15, 2005 to August 14, 2006. The drugs for the treatment of kidney cancer and renal cell carcinoma from Pfizer Inc. and Bayer AG and Onyx Pharmaceuticals Inc. have gained approval to be sold in Europe. Pfizer's...

  • COMPANY SPOTLIGHT - Onyx Pharmaceuticals, Inc.  // PharmaWatch: Cancer;Nov2009, Vol. 8 Issue 11, p24 

    The article presents a company profile for Onyx Pharmaceuticals Inc., a U.S.-based biopharmaceutical company engaged in research and development of drugs for cancer treatment. Nexavar or sorafenib, a kinase and angiogenesis inhibitor for targeting signal pathways for the proliferation of cancer...

  • Onyx/Bayer: Nexavar targets liver cancer.  // PharmaWatch: Cancer;Mar2007, Vol. 6 Issue 3, p15 

    The article focuses on the plan of Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals Inc. for the approval of the drug Nexavar as a first line treatment for metastatic hepatocellular carcinoma. The two companies have decided to file for approval after the drug conferred a statistically...

  • Bayer/Onyx: Nexavar to set the standard in liver cancer.  // PharmaWatch: Monthly Review;Jul2007, Vol. 6 Issue 7, p7 

    The article focuses on the effectiveness of the drug Nexavar from Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals Inc., as the drug significantly extend the overall survival in patients with previously untreated hepatocellular carcinoma in the U.S. It is stated that during the 43rd annual...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics